Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · IEX Real-Time Price · USD
7.41
+0.05 (0.68%)
At close: Apr 16, 2024, 4:00 PM
7.51
+0.10 (1.35%)
After-hours: Apr 16, 2024, 7:17 PM EDT

Fulcrum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Revenue
2.816.3419.168.82000
Revenue Growth (YoY)
-55.77%-66.90%117.19%----
Gross Profit
2.816.3419.168.82000
Selling, General & Admin
41.6741.6930.5221.3913.158.314.5
Research & Development
71.876.7869.759.0471.0725.1818.49
Other Operating Expenses
00.4300000
Operating Expenses
113.47118.9100.2280.4384.2233.522.99
Operating Income
-110.66-112.56-81.05-71.61-84.22-33.5-22.99
Other Expense / Income
-13.33-2.69-0.21-0.79-1.54-0.91-0.03
Pretax Income
-97.34-109.87-80.85-70.82-82.68-32.59-22.96
Net Income
-97.34-109.87-80.85-70.82-82.68-32.59-22.96
Preferred Dividends
00007.136.562.41
Net Income Common
-97.34-109.87-80.85-70.82-89.81-39.15-25.37
Shares Outstanding (Basic)
614535251111
Shares Outstanding (Diluted)
614535251111
Shares Change
36.27%27.23%39.47%129.53%778.76%76.79%-
EPS (Basic)
-1.59-2.44-2.29-2.79-8.13-31.14-35.68
EPS (Diluted)
-1.59-2.44-2.29-2.79-8.13-31.14-35.68
Free Cash Flow
-91.47-99.01-80.19-55-40.34-31.54-21.98
Free Cash Flow Per Share
-1.49-2.20-2.27-2.17-3.65-25.09-30.92
Gross Margin
100.00%100.00%100.00%100.00%---
Operating Margin
-3945.24%-1774.85%-422.97%-811.64%---
Profit Margin
-3470.05%-1732.43%-421.89%-802.66%---
Free Cash Flow Margin
-3261.07%-1561.23%-418.47%-623.34%---
EBITDA
-95.16-107.46-78.33-68.44-80.62-31.24-22.25
EBITDA Margin
-3392.62%-1694.37%-408.77%-775.70%---
Depreciation & Amortization
2.172.412.522.382.051.350.72
EBIT
-97.34-109.87-80.85-70.82-82.68-32.59-22.96
EBIT Margin
-3470.05%-1732.43%-421.89%-802.66%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).